Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Nexeon completes manufacturing facility

24 Apr 2014 07:00

RNS Number : 3752F
Imperial Innovations Group plc
24 April 2014
 



24 April 2014

 

Imperial Innovations Group plc

 

Nexeon completes commissioning of manufacturing facility

Imperial Innovations plc (AIM: IVO, "Innovations", "the Group") is pleased to note that its portfolio company Nexeon Ltd, has completed the construction and commissioning of its process development and manufacturing facility at its headquarters in Oxfordshire.  

Nexeon, which is Innovations' second largest portfolio company by value, is developing silicon anode technology for the next generation of lithium ion (Li-ion) batteries. Silicon anodes offer benefits over conventional carbon anodes as they enable the development of lithium-ion cells with greater energy density. Nexeon has established a growing portfolio of patents covering materials and fabrication processes.

The company's new manufacturing plant is capable of producing over 20 tonnes of product a year, and has been built to handle a wide range of materials and reagents. In addition to the manufacturing capability, the new facility includes integrated laboratories for Process Development and Material Characterisation.

Russ Cummings, CEO of Imperial Innovations, said:

"Nexeon's new 20 tonne plant is highly versatile, with end-use applications spanning consumer electronic devices and electric vehicles. We look forward to the company sampling customers with products from this advanced manufacturing facility."

Enquiries:

 

Imperial Innovations Group Plc

020 3053 8834

Russ Cummings, Chief Executive Officer

Jon Davies, Director of Communications

 

Instinctif Partners

020 7457 2020

Adrian Duffield/Mel Toyne-Sewell

 

J.P. Morgan Cazenove

020 7742 4000

Michael Wentworth Stanley/Alec Pratt

 

Cenkos Securities

020 7397 8900

Andy Roberts/Christopher Golden

 

 

Notes to editors

 

About Imperial Innovations - www.imperialinnovations.co.uk 

 

Imperial Innovations creates, builds and invests in pioneering technologies developed from the academic research of the UK's four leading Universities. The Group supports scientists and entrepreneurs in the commercialisation of their ideas and intellectual property by leading the formation of new companies, providing facilities in the early stages, providing investment and encouraging co-investment to accelerate development, providing operational expertise and recruiting high-calibre management teams. It also runs an Incubator in London that is the initial home for many of its technology spin-outs.

Originally formed as the Technology Transfer office for Imperial College - a role it still carries out today, Innovations also invests in opportunities arising from intellectual property developed at, or associated with, Cambridge University, Oxford University and University College London. These are the top four research intensive universities in Europe with a research income of over £1.3 billion per annum.

Innovations invests in the most promising opportunities from whichever technology sector they arise, but has built particular expertise in the key sectors of: therapeutics, medtech, engineering and materials, and ICT.

Since listing in 2006, Innovations has invested a total of £160.9 million across its portfolio companies, which have raised collectively investment of over £750.0 million. Innovations' largest holding is in Circassia Pharmaceuticals, which listed on the London Stock Exchange main market in March 2014 with a market capitalisation of £581.0 million.

About Nexeon

Nexeon Ltd. ('Nexeon') is a battery materials company developing silicon anodes for the next generation of lithium-ion rechargeable batteries. A spin out of Imperial Innovations, Nexeon scientists have shown that producing silicon with particular morphologies makes it possible to overcome its limitations as an anode material. Batteries made with silicon anodes have significant performance advantages over their traditional equivalents.

Nexeon is based in Oxfordshire, and has a fully automated and instrumented pilot plant that closely represents a commercial manufacturing facility, and allows an accurate understanding of the processes and costs associated with making anode materials. The technology has been conceived with a 'drop in' approach, requiring the minimum of changes to an existing Li-ion battery manufacturing operation.

Nexeon has established a growing portfolio of patents covering materials and fabrication processes, and is building a store of available know-how which is available through licensing.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAXLDAASLEFF
Date   Source Headline
30th May 20147:00 amRNSVeryan announces results on two-year Mimics study
22nd May 20147:00 amRNSYoyo closes £2.8 million seed investment round
6th May 20142:45 pmRNSHolding(s) in Company
24th Apr 20147:00 amRNSNexeon completes manufacturing facility
14th Apr 201412:00 pmRNSDirector change
3rd Apr 20143:36 pmRNSDirector's share purchase
28th Mar 20147:01 amRNSHalf Yearly Report
13th Mar 20141:04 pmRNSNotice of Results
13th Mar 20147:01 amRNSCircassia announces offer price
26th Feb 20147:40 amRNSCircassia indicative pricing notification
6th Feb 20147:03 amRNSCircassia announces intention to float
28th Jan 20147:00 amRNSAppointment of Joint Broker
7th Jan 20147:00 amRNSCell Medica achieves EU orphan drug designation
30th Dec 201310:00 amRNSFurther investment in TopiVert
18th Dec 20137:00 amRNS£5.1m funding round for Econic Technologies
17th Dec 201312:32 pmRNSResult of AGM
17th Dec 20139:00 amRNS£17.5m funding round for Crescendo Biologics
11th Dec 20137:00 amRNSIXICO launches first CE marked device
10th Dec 20137:00 amRNSSeed funding round for Cambridge spinout Aqdot
6th Dec 20137:00 amRNSGrant of share options
22nd Nov 20133:24 pmRNSOxford Immunotec trading commences on NASDAQ
20th Nov 20139:25 amRNSPulmocide receives £17m Series A funding
18th Nov 20137:00 amRNSMISSION Therapeutics receives £20m funding
16th Oct 20137:01 amRNSOxford Immunotec makes public S1 for potential IPO
16th Oct 20137:00 amRNSBoard Changes
16th Oct 20137:00 amRNSFinal Results
1st Oct 20139:00 amRNSCircassia grass allergy treatment success
26th Sep 20137:00 amRNSCell Medica opens commercial facility in Germany
23rd Sep 20137:05 amRNSIXICO expands into digital healthcare
23rd Sep 20137:00 amRNSProposed acquisition of IXICO Limited
20th Sep 20139:00 amRNSNotice of Results
12th Sep 20137:00 amRNSCircassia phase II clinical study success
10th Sep 20137:00 amRNSLeads £8m funding round in Plaxica
29th Aug 20137:00 amRNSInvestment in new mobile payments business
12th Aug 20136:01 pmRNSDirector/PDMR Shareholding
26th Jul 20138:45 amRNSPortfolio company PolyTherics merges with Antitope
17th Jul 20137:00 amRNSDirectorate Change
2nd Jul 20137:00 amRNS£30m loan from EIB for healthcare investment
25th Jun 20137:00 amRNSInvestment in PsychologyOnline
4th Jun 20137:00 amRNSAutifony starts phase I trial
8th May 20137:00 amRNSCell Medica treats first patient in new trial
29th Apr 20137:00 amRNSInvestment team appointment
17th Apr 20139:26 amRNSBoard change
22nd Mar 20137:00 amRNSHalf year results
1st Mar 20139:22 amRNSNotice of Results
1st Mar 20138:38 amRNSNotification of major interest in shares
25th Feb 20137:00 amRNSCircassia's cat allergy treatment
14th Feb 20137:00 amRNSInvestment in new technology company
23rd Jan 20137:00 amRNS£1.5m investment in new software portfolio company
21st Jan 20133:45 pmRNSListing of shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.